Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: A prospective combination of ABT-737 and TMZ for treating glioma

International Journal of Oncology

Volumn 46, Issue 3, 2015, Pages 1304-1316

  Yang, Ming Chang ^b,c   Loh, Joon Khim ^a,d   Li, Yi Yang ^a,b   Huang, Wen Sheng ^a   Chou, Chia Hua ^a,b   Cheng, Jiin Tsuey ^b   Wang, Yeng Tseng ^a   Lieu, Ann Shung ^d   Howng, Shen Long ^d   Hong, Yi Ren ^a,b   Chou, An Kuo ^e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Bcl2 family proteins; Bcl2L12; BH3 like domain; Glioma multiforme

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BCL2L12 PROTEIN; BH3 PROTEIN; CASPASE 3; CYTOCHROME C; PROTEIN BCL 2; PROTEIN BCL XL; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ABT-737; ANTINEOPLASTIC AGENT; BAX PROTEIN (53-86); BCL2 PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; BCL2L12 PROTEIN, HUMAN; BIPHENYL DERIVATIVE; DACARBAZINE; MUSCLE PROTEIN; NITROPHENOL; ONCOPROTEIN; PEPTIDE FRAGMENT; PIPERAZINE DERIVATIVE; PROTEIN BCL X; PROTEIN BINDING; SULFONAMIDE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; ENZYME REACTIVATION; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL CULTURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AUTOPHAGY; BCL-X PROTEIN; BIPHENYL COMPOUNDS; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS; MODELS, MOLECULAR; MUSCLE PROTEINS; NITROPHENOLS; PEPTIDE FRAGMENTS; PIPERAZINES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 84921923083     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2838     Document Type: Article

References (44)

1. Van Meir EG, Hadjipanayis CG, Norden AD, Shu H-K, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166-193, 2010.
2. Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM and Davis FG: Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro Oncol 1: 14-25, 1999.
3. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
4. Wang X: The expanding role of mitochondria in apoptosis. Genes Dev 15: 2922-2933, 2001.
5. Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55: 178-194, 2005.
6. Youle RJ and Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
7. Yip KW and Reed JC: Bcl-2 family proteins and cancer. Oncogene 27: 6398-6406, 2008.
8. Green DR and Chipuk JE: Apoptosis: stabbed in the BAX. Nature 455: 1047-1049, 2008.
9. Cheng EH, Wei MC, Weiler S, et al: BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8: 705-711, 2001.
10. Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999.
11. Kim H, Rafiuddin-Shah M, Tu H-C, et al: Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8: 1348-1358, 2006.
12. Wei MC, Lindsten T, Mootha VK, et al: tBID, a membranetargeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 14: 2060-2071, 2000.
13. Wei MC, Zong WX, Cheng EH, et al: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727-730, 2001.
14. Willis SN, Chen L, Dewson G, et al: Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294-1305, 2005.
15. Walensky LD: Playing fullBAK. Cell Cycle 12: 1333-1334, 2013.
16. Certo M, Del Gaizo Moore V, Nishino M, et al: Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9: 351-365, 2006.
17. Kuwana T, Bouchier-Hayes L, Chipuk JE, et al: BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17: 525-535, 2005.
18. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S and Korsmeyer SJ: Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2: 183-192, 2002.
19. Kim H, Tu H-C, Ren D, et al: Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell 36: 487-499, 2009.
20. Sattler M, Liang H, Nettesheim D, et al: Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275: 983-986, 1997.
21. Walensky LD: BCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ 13: 1339-1350, 2006.
22. Scorilas A, Kyriakopoulou L, Yousef GM, Ashworth LK, Kwamie A and Diamandis EP: Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. Genomics 72: 217-221, 2001.
23. Chou C-H, Chou A-K, Lin C-C, et al: GSK3β regulates Bcl2L12 and Bcl2L12A anti-apoptosis signaling in glioblastoma and is inhibited by LiCl. Cell Cycle 11: 532-542, 2012.
24. Stegh AH, Brennan C, Mahoney JA, et al: Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev 24: 2194-2204, 2010.
25. Hong Y, Yang J, Wu W, et al: Knockdown of BCL2L12 leads to cisplatin resistance in MDA-MB-231 breast cancer cells. Biochim Biophys Acta 1782: 649-657, 2008.
26. Thomadaki H, Talieri M and Scorilas A: Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Lett 247: 48-55, 2007.
27. Florou D, Papadopoulos IN and Scorilas A: Molecular analysis and prognostic impact of the novel apoptotic gene BCL2L12 in gastric cancer. Biochem Biophys Res Commun 391: 214-218, 2010.
28. Furnari FB, Fenton T, Bachoo RM, et al: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710, 2007.
29. Lin CJ, Lee CC, Shih YL, et al: Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med 52: 377-391, 2012.
30. Czabotar PE, Lee EF, Thompson GV, Wardak AZ, Fairlie WD and Colman PM: Mutation to Bax beyond the BH3 domain disrupts interactions with pro-survival proteins and promotes apoptosis. J Biol Chem 286: 7123-7131, 2011.
31. Roy A, Xu D, Poisson J and Zhang Y: A protocol for computerbased protein structure and function prediction. JoVE: e3259, 2011.
32. Yachdav G, Kloppmann E, Kajan L, et al: PredictProtein - an open resource for online prediction of protein structural and functional features. Nucleic Acids Res 42: W337-W343, 2014.
33. Bhat V, Olenick MB, Schuchardt BJ, Mikles DC, McDonald CB and Farooq A: Molecular determinants of the binding specificity of BH3 ligands to BclXL apoptotic repressor. Biopolymers 101: 573-582, 2014.
34. Czabotar PE, Westphal D, Dewson G, et al: Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell 152: 519-531, 2013.
35. Wysoczanski P, Mart RJ, Loveridge EJ, et al: NMR solution structure of a photo-switchable apoptosis activating Bak peptide bound to Bcl-xL. J Am Chem Soc 134: 7644-7647, 2012.
36. Petros AM, Medek A, Nettesheim DG, et al: Solution structure of the antiapoptotic protein bcl-2. Proc Natl Acad Sci USA 98: 3012-3017, 2001.
37. Suzuki M, Youle RJ and Tjandra N: Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 103: 645-654, 2000.
38. Stegh AH, Kim H, Bachoo RM, et al: Bcl2L12 inhibits postmitochondrial apoptosis signaling in glioblastoma. Genes Dev 21: 98-111, 2007.
39. Stegh AH, Kesari S, Mahoney JE, et al: Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA 105: 10703-10708, 2008.
40. Stegh AH and DePinho RA: Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma. Cell Cycle 10: 33-38, 2011.
41. Hong YR: False positive: detection and elimination. In: Yeast Hybrid Methods. Zhu L and Hannon G (eds). Eaton publishing, Natick, MA, pp101-113, 2000.
42. Higgins GC, Devenish RJ, Beart PM and Nagley P: Autophagic activity in cortical neurons under acute oxidative stress directly contributes to cell death. Cell Mol Life Sci 68: 3725-3740, 2011.
43. Simonin K, N'Diaye M, Lheureux S, et al: Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Apoptosis 18: 492-508, 2013.
44. Oltersdorf T, Elmore SW, Shoemaker AR, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681, 2005.